Ventilator Acquired Pneumonia
14
1
1
8
Key Insights
Highlights
Success Rate
89% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
7.1%
1 terminated out of 14 trials
88.9%
+2.3% vs benchmark
7%
1 trials in Phase 3/4
13%
1 of 8 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.6%
Based on 8 completed trials
Clinical Trials (14)
Procalcitonin Versus Serum Zinc for Diagnosis of Ventilator-Associated Pneumonia in ICU Patients
ClusterVAP: Multicentre Proteomic Endotyping of Ventilator-associated Pneumonia
Steriwave ICU Pilot Study
Evidence-Based Nursing to Reduce Adverse Events Regarding Ventilator Associated Pneumonia, Pressure Injuries and Central Line Bloodstream Infection in Intensive Care Unit in Bangladesh
Effect of Use of Probiotics on Systemic Infection in Critically Ill Patients: a Double Blind, Randomized, Placebo-controlled Trial
Real-World Study of Ceftazidime Avibactam in China
Assessment of the Role of Probiotics in Prevention of Ventilator-Associated Pneumonia in Neonates
Intravenous Metoprolol in Septic Shock
Bronchial Colonization With Fungi and Late Respiratory Acquired Pneumonia
Study to Determine Quicker Methods of Diagnosing Pneumonia Caused by a Breathing Machine in Critically Ill Patients
Comparison of Two Strategies of Oropharyngeal and Tracheal Suctioning in Mechanically Ventilated Patients
Cost Effectiveness Of Linezolid In Central America
Direct E-test on Bronchoalveolar Lavage From Patients With Ventilator-acquired Pneumonia
Ontario ICU Clinical Best Practices Demonstration Project